Clients trust me with their strategic projects in the areas of M&A (including private share and asset sales and acquisitions, private equity transactions, public mergers & acquisitions, debt and equity funding and capital markets transactions), commercial negotiations, and advising on corporate and governance issues.
I work across a spectrum of industries, including technology, media, infrastructure, real estate, financial services and insurance, government, mining and resources, sport, pharmaceuticals, agriculture, consumer goods and food manufacturing.
Clients value me for being accessible, efficient, commercial, giving them ongoing visibility on costs, and being easy to work with.
Given that cyber security is now mission-critical for all businesses, I established and lead the Addisons cyber and data security practice. Addisons participates in an innovative alliance with technical and crisis management experts to deliver a holistic cyber security solution, suitable for businesses of all sizes.
LLB (Hon) - University of Sydney
BEcon/BSoSc - University of Sydney
Addisons helps Bega win battle over peanut butter packaging
03 May 2019
On 1 May 2019 the Federal Court of Australia confirmed Bega Cheese’s right to continue to use the packaging get-up or trade dress associated with the peanut butter products that it acquired as part of its purchase of the Mondelez Grocery Business in 2017. Importantly, this gives Bega Cheese the right to continue to use the current packaging of its Smooth and Crunchy Peanut Butter products.
Unilever all in a sweat over new player's 'clinical' efficacy claims
20 May 2019
The Federal Court recently examined whether representations alleged by Unilever to have been made by Beiersdorf about Beiersdorf’s Nivea ‘Stress Protect Clinical Strength’ deodorant were false, misleading or deceptive under the Australian Consumer Law . Whilst Unilever was ultimately unsuccessful, the case provides useful guidance on the use of the term ‘clinical’ as a product descriptor and what sort of scientific substantiation is required to support a ‘clinical’ claim.
Time to Whet your Whistle
15 May 2019
Sailing through parliament, the impending whistleblower amendments are due to commence on 1 July 2019. But stormy seas abound for public and large proprietary companies, who will be required to amend their existing whistleblower policies to comply with the new legislation.
Equity derivative positions back on the table - do you need to disclose your holdings? The Takeovers Panel considers revising its Guidance Note 20 on disclosure of equity derivatives
14 May 2019
The topic of disclosure of equity derivative positions is back on the table following the release by the Takeovers Panel of proposed revisions to its Guidance Note 20 (Equity Derivatives).